Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Novo Nordisk A/S — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $15.69 (market cap $1.06B), while Novo Nordisk A/S trades at $38.12 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 156× YieldMax MSTR Option Income Strategy ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while YieldMax MSTR Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax MSTR Option Income Strategy ETF for 30 Days and Novo Nordisk A/S for 116 Days on average.
| MSTY | NVO | |
|---|---|---|
Market Cap | $1.06B | $165.31B |
Volume | 2,402,888 | 11,432,838 |
Sector | Income / Options Overlay | Health |
52-Week High | $67.85 | $63.98 |
52-Week Low | $11.55 | $35.29 |
Typical Hold Time | 30 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.83, down 5.61% today amid bearish technical signals. The ETF shows mixed sentiment with Seeking Alpha rating it Hold despite a 100.32% annualized distribution rate. Recent articles highlight significant NAV erosion, with $10,000 investments declining to approximately $6,614 over six months according to 24/7 Wall Street analysis from July 2026.
The fund's high distribution strategy comes with substantial principal erosion risk. While weekly dividends provide income, the structural design returns investor capital as distributions. Analyst consensus remains cautious due to the fund's dependence on MSTR volatility and ongoing NAV decline, making this suitable only for sophisticated investors understanding the income-principal tradeoff.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
